Celgene to buy Receptos for $7.2 billion; gains promising drug
0
(Reuters) - Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis.